1. Executive Summary

2. Worldwide Number of Persons Vaccinated with Influenza Vaccines and Forecast (2013 - 2027)

3. Worldwide Influenza Vaccines Market Revenue and Forecast (2013 - 2027)

4. Worldwide Influenza Vaccines Market Share and Y-o-Y Growth (%)
4.1 Number of Persons Vaccinated with Influenza Vaccines Share,2013 - 2027(%)
4.2 Influenza Vaccines Market Share,2013 - 2027(%)

5. Worldwide Influenza Vaccines Market Drivers and Inhibitors
5.1 Market Drivers
5.2 Market Inhibitors

6. Worldwide Influenza Vaccines Market, By Geography (Volume and Value),2013 - 2027
6.1 United States
6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.1.2 United States Influenza Vaccines Market Revenue (2013 - 2027)
6.2 Canada
6.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.2.2 Canada Influenza Vaccines Market Revenue (2013 - 2027)
6.3 Germany
6.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.3.2 Germany Influenza Vaccines Market Revenue (2013 - 2027)
6.4 France
6.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.4.2 France Influenza Vaccines Market Revenue (2013 - 2027)
6.5 Italy
6.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.5.2 Italy Influenza Vaccines Market Revenue (2013 - 2027)
6.6 Spain
6.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.6.2 Spain Influenza Vaccines Market Revenue (2013 - 2027)
6.7 United Kingdom
6.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.7.2 United Kingdom Influenza Vaccines Market Revenue (2013 - 2027)
6.8 Netherlands
6.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.8.2 Netherlands Influenza Vaccines Market Revenue (2013 - 2027)
6.9 Sweden
6.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.9.2 Sweden Influenza Vaccines Market Revenue (2013 - 2027)
6.10 Denmark
6.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.10.2 Denmark Influenza Vaccines Market Revenue (2013 - 2027)
6.11 Poland
6.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.11.2 Poland Influenza Vaccines Market Revenue (2013 - 2027)
6.12 Norway
6.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.12.2 Norway Influenza Vaccines Market Revenue (2013 - 2027)
6.13 Finland
6.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.13.2 Finland Influenza Vaccines Market Revenue (2013 - 2027)
6.14 Ireland
6.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.14.2 Ireland Influenza Vaccines Market Revenue (2013 - 2027)
6.15 Belgium
6.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.15.2 Belgium Influenza Vaccines Market Revenue (2013 - 2027)
6.16 Australia
6.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.16.2 Australia Influenza Vaccines Market Revenue (2013 - 2027)
6.17 New Zealand
6.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.17.2 New Zealand Influenza Vaccines Market Revenue (2013 - 2027)
6.18 Japan
6.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.18.2 Japan Influenza Vaccines Market Revenue (2013 - 2027)
6.19 Brazil
6.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.19.2 Brazil Influenza Vaccines Market Revenue (2013 - 2027)
6.20 China
6.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.20.2 China Influenza Vaccines Market Revenue (2013 - 2027)
6.21 India
6.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.21.2 India Influenza Vaccines Market Revenue (2013 - 2027)
6.22 Rest of the World (ROW)
6.22.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027)
6.22.2 ROW Influenza Vaccines Market Revenue (2013 - 2027)

7. Recent Development in the Worldwide Influenza Vaccines Market

8. Worldwide Influenza Vaccines Market - Regulatory System
8.1 United States
8.2 Europe
8.3 Japan

9. Major Deals in the Worldwide Influenza Vaccines Market
9.1 Merger and Acquisitions
9.2 Collaboration Deals
9.3 Licensing Agreement
9.4 Exclusive Agreement
9.5 Distribution Agreement

10. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
10.1 Year 2020
10.2 Year 2019

11. Key Companies Analysis
11.1 Sanofi Pasteur
11.1.1 Business Overview
11.1.2 Influenza Vaccines Portfolio
11.1.3 Influenza Vaccines Value Sales Analysis
11.1.4 Promising Influenza Vaccines in the Clinical Development
11.1.5 Recent Development
11.2 GlaxoSmithKline (GSK)
11.2.1 Business Overview
11.2.2 Influenza Vaccines Portfolio
11.2.3 Influenza Vaccines Sales Value Analysis
11.2.4 Recent Development
11.3 Seqirus (CSL Limited)
11.3.1 Business Overview
11.3.2 Influenza Vaccines Portfolios
11.3.3 Influenza Vaccines Sales Value Analysis
11.3.4 Promising Influenza Vaccines in the Clinical Development
11.3.5 Recent Development
11.4 AstraZeneca
11.4.1 Business Overview
11.4.2 Influenza Vaccines Portfolio
11.4.3 Influenza Vaccines Sales Value Analysis
11.4.4 Recent Development
11.5 Gamma Vaccines Pty Ltd
11.5.1 Business Overview
11.5.2 Influenza Vaccines Portfolio
11.5.3 Recent Development
11.6 Hualan Biological Engineering Inc
11.6.1 Business Overview
11.6.2 Influenza Vaccines Portfolio
11.6.3 Recent Development
11.7 Shanghai Institute of Biological Products Co., Ltd.
11.7.1 Business Overview
11.7.2 Influenza Vaccine Portfolio
11.8 Mylan
11.8.1 Business Overview
11.8.2 Influenza Vaccine Portfolio
11.9 BioDiem
11.9.1 Business Overview
11.9.2 Influenza Vaccine Portfolio
11.9.3 Recent Development

12. Emerging Players
12.1 Novavax
12.1.1 Business Overview
12.1.2 Promising Influenza Vaccines in the Clinical Development
12.1.3 Recent Development
12.2 BiondVax Pharmaceuticals Ltd.
12.2.1 Business Overview
12.2.2 Promising Influenza Vaccines in the Clinical Development
12.2.3 Recent Development
12.3 Medicago
12.3.1 Business Overview
12.3.2 Promising Influenza Vaccines in the Clinical Development
12.3.3 Recent Development
12.4 Moderna Inc
12.4.1 Business Overview
12.4.2 Promising Influenza Vaccines in the Clinical Development
12.4.3 Recent Development
12.5 Pneumagen
12.5.1 Business Overview
12.5.2 Promising Influenza Vaccines in the Clinical Development
12.5.3 Recent Development
12.6 Altimmune
12.6.1 Business Overview
12.6.2 Promising Influenza Vaccines in the Clinical Development
12.6.3 Recent Development
12.7 Daiichi Sankyo
12.7.1 Business Overview
12.7.2 Promising Influenza Vaccines in the Clinical Development
12.7.3 Recent Development
12.8 FluGen
12.8.1 Business Overview
12.8.2 Promising Influenza Vaccines in the Clinical Development
12.8.3 Recent Development
12.9 Imutex
12.9.1 Business Overview
12.9.2 Promising Vaccines in the Clinical Development